Back to top
more

BioLineRx (BLRX)

(Real Time Quote from BATS)

$0.65 USD

0.65
198,590

+0.04 (6.28%)

Updated Apr 29, 2024 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 61 - 80 ( 202 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 61

05/03/2017

Daily Note

Pages: 5

Stage Now Set to Go Pivotal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 62

04/18/2017

Company Report

Pages: 6

Pipeline Expanding as Expected; Coffers Filled to the Brim; Target Raised to $4

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 63

04/18/2017

Company Report

Pages: 6

Pipeline Expanding as Expected; Coffers Filled to the Brim; Target Raised to $4

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 64

02/23/2017

Company Report

Pages: 7

While ''8040 Continues its March Forward, It''s the Year of Background BD and Focus; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 65

02/23/2017

Company Report

Pages: 7

While ''8040 Continues its March Forward, It''s the Year of Background BD and Focus; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 66

02/13/2017

Company Report

Pages: 25

Initiating Coverage at Buy Rating

Provider: Rodman & Renshaw, Co.

Price: 75.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 67

02/13/2017

Company Report

Pages: 25

Looking for BL-8040 to Rule the Roost; Enticing Shots on Goal; Initiating Coverage at Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 68

12/19/2016

Company Report

Pages: 4

We are transferring coverage of BLRX to Sa''ar Yaniv, due to the departure of the covering analyst and placing shares Under Review

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 69

12/06/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 70

12/05/2016

Company Report

Pages: 11

''8040 One Two Punch Highlighted at ASH; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 71

11/28/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 72

11/28/2016

Industry Report

Pages: 10

ROTH Healthcare Monthly - Longing for Better Blood at ASH

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 73

11/22/2016

Company Report

Pages: 7

3Q16 Results; Cash Strong and Upcoming Data Rich; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 74

11/21/2016

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 75

11/21/2016

Company Report

Pages: 4

Rolling Out Another License with Novartis Collaboration

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 76

11/01/2016

Industry Report

Pages: 9

Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 77

10/11/2016

Industry Report

Pages: 8

Healthcare: Inaugural Healthcare Monthly; Catalysts Galore

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 78

09/26/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 79

09/23/2016

Daily Note

Pages: 4

Pipeline Expands with Novartis Collaboration; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 80

09/23/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party